Revolutionizing the Treatment of Early Stage Mycosis Fungoides

  • CEO: Stephen Tullman
  • Location: Malvern, PA
  • Milestones: Jun 2012 - Third Point Ventures initial investment, Aug 2013 - Ceptaris acquired by Actelion Pharmaceuticals (SIX Swiss Exchange: ATLN)
Go to site

Ceptaris was a privately held, specialty pharmaceutical company established to develop Valchlor, a proprietary gel formulation of mechlorethamine for the treatment of early stage mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL).